Annovis Bio Inc.
This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.
ANVS-26001 will be a 24-month open-label safety study. Qualified participants will receive buntanetap 30 mg daily after a screening period of up to 42 days. ADAS-Cog13, ADCS-iADL, CDR, MMSE, WAIS-Coding, NPI-12, QoL-AD, CGI-S, and C-SSRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. An independent Data and Safety Monitoring Board (DSMB) will assess treatment safety.
Inclusion Criteria: 1. Has participated in a prior Alzheimer's clinical trial with buntanetap. 2. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (minimum 10 hours per week), and will accompany the participant on study visits at designated times. 3. Female participants of childbearing potential must have a negative urine pregnancy test at screening, be non-lactating, and must agree to use a highly effective method of contraception. 4. Male participants must be sterile or sexually inactive or agree not to father a child…
buntanetap 30 mg daily